GLEASON PATHOLOGICAL SCALE FOR PROSTATE CANCER AND ITS MODIFICATIONS
Keywords:
Gleason, gradation system, prostate cancerAbstract
The Gleason scoring system is a tool widely used today due to its adequate prognostic and treatment orientation in the evaluation of prostatic adenocarcinoma. This scale has suffered several modifications since its beginnings in the sixties as well as in recent years, which seek to facilitate and homogenize the pathological criteria of each of its categories.
References
1. Longo, D., Fauci, A., Kasper, D., Hauser, S., Jameson, J., & Loscalzo, J. (2016). Harrison Principios de Medicina Interna (19va edición ed.). Mc Graw Hill.
2. DeVita, V., Lawrence, T., & Rosenberg, S. (2015). Cancer Principles & Practice of Oncology (10ma edición ed.). Wolters Kluwer Health.
3. Pierorazio, P., Walsh, P., Partin, A., & Epstein, J. (2013). Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. National Institutes of Health Public Access, 111(5), 753-760.
4. Chen, N., & Zhou, Q. (2016). The evolving Gleason grading system. Chinese Journal of Cancer Research, 28(1), 58-64.
5. Wein, A., Kavoussi, L., Novick, A., Partin, A., & Peters, C. (2016). Campbell-Walsh Urología (10ma edición ed., Vol. Tomo 3). Editorial Médica Panamericana .
6. Srigley, J., Delahunt, B., Egevad, L., Samaratunga, H., Yaxley, J., & Evans, A. (2016). One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association, 10(9-10), 339-341.
7. Nakai, Y., Tanaka, N., Shimada, K., Konishi, N., Miyake, M., Anai, S., & Fujimoto, K. (2015). Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. BioMed Central Urology, 15(70), 2-7.
8. Epstein, J. (2014). Once again Gleason remains the grading system to beat: a comparison with using percentage pattern 4/5. BJU International, 113(3), 353.
9. Rubin, M., Girelli, G., & Demichelis, F. (2016). Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. European Association of Urology, 69(1), 557-560.
10. Gordetsky, J., & Epstein, J. (2016). Grading of prostatic adenocarcinoma: current state and prognostic implications. BioMed Central Diagnostic Pathology, 11(25), 2-8.
2. DeVita, V., Lawrence, T., & Rosenberg, S. (2015). Cancer Principles & Practice of Oncology (10ma edición ed.). Wolters Kluwer Health.
3. Pierorazio, P., Walsh, P., Partin, A., & Epstein, J. (2013). Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. National Institutes of Health Public Access, 111(5), 753-760.
4. Chen, N., & Zhou, Q. (2016). The evolving Gleason grading system. Chinese Journal of Cancer Research, 28(1), 58-64.
5. Wein, A., Kavoussi, L., Novick, A., Partin, A., & Peters, C. (2016). Campbell-Walsh Urología (10ma edición ed., Vol. Tomo 3). Editorial Médica Panamericana .
6. Srigley, J., Delahunt, B., Egevad, L., Samaratunga, H., Yaxley, J., & Evans, A. (2016). One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association, 10(9-10), 339-341.
7. Nakai, Y., Tanaka, N., Shimada, K., Konishi, N., Miyake, M., Anai, S., & Fujimoto, K. (2015). Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. BioMed Central Urology, 15(70), 2-7.
8. Epstein, J. (2014). Once again Gleason remains the grading system to beat: a comparison with using percentage pattern 4/5. BJU International, 113(3), 353.
9. Rubin, M., Girelli, G., & Demichelis, F. (2016). Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer. European Association of Urology, 69(1), 557-560.
10. Gordetsky, J., & Epstein, J. (2016). Grading of prostatic adenocarcinoma: current state and prognostic implications. BioMed Central Diagnostic Pathology, 11(25), 2-8.
Downloads
Published
2020-11-12
Issue
Section
Literature review
License
The intellectual property of accepted works belongs to their authors, however access to them is totally open and free, so they can be reproduced totally or partially with the only limitation of recognizing the authorship and the source of publication (Revista Medicina Legal de Costa Rica), as long as said exploitation does not have commercial character.
How to Cite
GLEASON PATHOLOGICAL SCALE FOR PROSTATE CANCER AND ITS MODIFICATIONS. (2020). Medicina Legal De Costa Rica, 34(1). https://www.binasss.sa.cr/ojssalud/index.php/mlcr/article/view/48
